Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/927653/000092765322000051/mck-20220331.htm
May 2022
April 2022
April 2022
February 2022
February 2022
February 2022
January 2022
November 2021
October 2021
September 2021
Third-Quarter | Year-to-Date | |||||||||||||||||||||||||||||||||||||
($ in millions, except per share amounts) | FY22 | FY21 | Change | FY22 | FY21 | Change | ||||||||||||||||||||||||||||||||
Revenues | $ | 68,614 | $ | 62,599 | 10 | % | $ | 197,864 | $ | 179,086 | 10 | % | ||||||||||||||||||||||||||
Income (loss) from Continuing Operations 1 | (7) | (6,226) | (100) | 749 | (5,204) | 114 | ||||||||||||||||||||||||||||||||
Adjusted Earnings 1,2 | 944 | 741 | 27 | 2,782 | 1,978 | 41 | ||||||||||||||||||||||||||||||||
Earnings (loss) per Diluted Share 1 | (0.04) | (39.03) | (100) | 4.81 | (32.28) | 115 | ||||||||||||||||||||||||||||||||
Adjusted Earnings per Diluted Share 1,2 | 6.15 | 4.60 | 34 | 17.86 | 12.17 | 47 | ||||||||||||||||||||||||||||||||
1 Reflects continuing operations attributable to McKesson, net of tax 2 Represents a non-GAAP financial measure; refer to the reconciliations of non-GAAP financial measures included in accompanying schedules |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/927653/000092765322000051/mck-20220331.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Mckesson Corp.
Mckesson Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Rating
Learn More![]()
CRITICAL ACCOUNTING POLICIES AND ESTIMATES We consider an accounting estimate to be critical if the estimate requires us to make assumptions about matters based upon past experience and management's judgment that were uncertain at the time the accounting estimate was made and if different estimates that we reasonably could have used in the current period, or changes in the accounting estimate that are reasonably likely to occur from period to period, could have a material impact on our financial condition or results from operations.
Any material changes in key assumptions, including failure to meet business plans, negative changes in government reimbursement rates, deterioration in the U.S. and global financial markets, an increase in interest rates or an increase in the cost of equity financing by market participants within the industry, or other unanticipated events and circumstances may decrease the projected cash flows or increase the discount rates and could potentially result in an impairment charge.
Total Operating Expenses A summary and description of the components of our total operating expenses for the years ended March 31, 2022 and 2021 is as follows: Selling, distribution, general, and administrative expenses ("SDG&A"): SDG&A consists of personnel costs, transportation costs, depreciation and amortization, lease costs, professional fee expenses, administrative expenses, remeasurement charges to the lower of carrying value or fair value less costs to sell, and other general charges.
The decrease in Corporate expenses, net was partially offset by $274 million recorded in 2022 related to our estimated liability for opioid-related claims, a net gain of $131 million recognized in 2021 in connection with insurance proceeds received from the settlement of the shareholder derivative action related to our controlled substances monitoring program, and fair value remeasurement charges related to our E.U. disposal group and our U.K. disposal group.
However, other risks, expenses, and future developments, such as additional government actions, increased regulatory uncertainty, and material changes in key market assumptions limit our ability to estimate projected cash flows, which could adversely affect the fair value of various reporting units in future periods, including our McKesson Canada reporting unit within our International segment, where the risk of material goodwill impairment is higher than other reporting units.
Material changes to key assumptions...Read more
Other risks, expenses, and future...Read more
Generally, a decline in estimated...Read more
Gross Profit Gross profit increased...Read more
Indicators that are considered include...Read more
Corporate 2022 vs. 2021 Corporate...Read more
Our ongoing consideration of all...Read more
In addition, certain charges related...Read more
Impact to our Results of...Read more
On July 23, 2021, we...Read more
Gross profit was favorably impacted...Read more
See Item 1 - Business...Read more
During the year ended March...Read more
MD&A Index McKESSON CORPORATION FINANCIAL...Read more
Excluding the aforementioned classifications, operating...Read more
Medical-Surgical Solutions 2022 vs. 2021...Read more
Revenues for this segment were...Read more
When the net realizable value...Read more
If all conditions to the...Read more
Gross profit was also driven...Read more
Our debt to capital ratio...Read more
Refer to the "Restructuring Initiatives...Read more
Medical-Surgical Solutions 2022 vs. 2021...Read more
Prescription Technology Solutions 2022 vs....Read more
Corporate expenses, net for the...Read more
MD&A Index McKESSON CORPORATION FINANCIAL...Read more
Interest Expense Interest expense decreased...Read more
We recognized higher sales for...Read more
MD&A Index McKESSON CORPORATION FINANCIAL...Read more
NEW ACCOUNTING PRONOUNCEMENTS New accounting...Read more
Consolidated working capital improved at...Read more
Operating loss for the year...Read more
Our debt to capital ratio...Read more
That Form 8-K should be...Read more
Cost inflation during 2022 generally...Read more
A material default in payment,...Read more
At March 31, 2022, the...Read more
These factors could make our...Read more
While we are not able...Read more
We have not observed a...Read more
Charges incurred for this initiative...Read more
Operating activities for the year...Read more
Revenues for this segment were...Read more
Income Tax (Benefit) Expense We...Read more
International 2022 vs. 2021 Operating...Read more
Any significant changes in assumptions...Read more
During the third quarter of...Read more
The fair value of a...Read more
Overall, during 2022 we had...Read more
MD&A Index McKESSON CORPORATION FINANCIAL...Read more
The Settlement became effective on...Read more
Under the Domination Agreement, the...Read more
The various responses we put...Read more
However, there can be no...Read more
In discussing our operating results,...Read more
The recovery of prescription volume...Read more
The recovery from the pandemic...Read more
However, the likelihood of a...Read more
Because of the many uncertainties...Read more
In future periods, fair value...Read more
During the year ended March...Read more
These assumptions require significant judgment...Read more
MD&A Index McKESSON CORPORATION FINANCIAL...Read more
Trends and Uncertainties: The Impact...Read more
We believe that our future...Read more
MD&A Index McKESSON CORPORATION FINANCIAL...Read more
If our current estimate of...Read more
Operating loss for the year...Read more
Share Repurchase Plans The Board...Read more
As of March 31, 2022,...Read more
We believe that we have...Read more
Other Income, Net Other income,...Read more
Refer to Item 1A -...Read more
Our reported income tax (benefit)...Read more
At March 31, 2021, the...Read more
At March 31, 2022, we...Read more
In estimating future taxable income,...Read more
Goodwill and Long-Lived Assets: Goodwill...Read more
Assumptions and estimates about future...Read more
Restructuring Initiatives and Long-Lived Asset...Read more
The average price paid per...Read more
Long-Lived Assets Currently, all of...Read more
(3)Of the total dollar value,...Read more
An increase or decrease of...Read more
During the first quarter of...Read more
If we had used the...Read more
International 2022 vs. 2021 International...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Mckesson Corp provided additional information to their SEC Filing as exhibits
Ticker: MCK
CIK: 927653
Form Type: 10-K Annual Report
Accession Number: 0000927653-22-000051
Submitted to the SEC: Mon May 09 2022 8:15:36 AM EST
Accepted by the SEC: Mon May 09 2022
Period: Thursday, March 31, 2022
Industry: Wholesale Drugs Proprietaries And Druggists Sundries